Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hematol Oncol
Главные авторы: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W. N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2017
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5322633/
https://ncbi.nlm.nih.gov/pubmed/28228106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0417-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы